Oxolife’s infertility pill increased IVF success by over 10% in Phase II trial
The Phase II results showed that the company’s infertility pill improved pregnancy and live birth rates by 10.6% and 6.9%, respectively.
08 July 2024
08 July 2024
The Phase II results showed that the company’s infertility pill improved pregnancy and live birth rates by 10.6% and 6.9%, respectively.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional chronic kidney disease markets through 2033. Per our estimates, the sales of CKD therapeutics across the 7MM will grow at a CAGR of >19% between 2023 and 2033. The launch of eight oral pipeline agents and six injectable pipeline agents will be the main drivers of the CKD market across the 7MM.
Give your business an edge with our leading industry insights.